Mobocertinib
Targeted TherapyApproved for: NSCLCBiomarker: EGFR Exon20 Insertion Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC Related Research News FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLCClinical Research Demonstrates Positive...